● Recruiting

A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)

Condition: Breast Cancer · Sponsor: M.D. Anderson Cancer Center

PhasePhase 1

Planned participants24

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

The goal of this clinical research study is to find the best dose of the drugs cyclophosphamide and axatilimab that can be given in combination with the standard dose of retifanlimab to patients with metastatic TNBC.

This description comes directly from the study's public registry record.

Talk to the study team

Bora Lim, MD · (713) 745-0689 · blim@mdanderson.org

Angela Alexander · 832-450-5265

Always discuss trial participation with your own doctor first.

Locations (1)

The University of Texas M. D. Anderson Cancer Center

Houston, Texas, United States

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06959537